Results 61 to 70 of about 9,514 (200)

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Outcome of therapy-related myeloid neoplasms treated with azacitidine

Journal of Hematology & Oncology, 2012
Background Therapy-related myeloid neoplasms (t-MN), including myelodysplastic syndromes and acute myeloid leukemia (t-MDS and t-AML) are associated to clinical and biologic unfavorable prognostic features, including high levels of DNA methylation ...
Fianchi Luana, Criscuolo Marianna, Lunghi Monia, Gaidano Gianluca, Breccia Massimo, Levis Alessandro, Finelli Carlo, Santini Valeria, Musto Pellegrino, Oliva Esther N, Leoni Pietro, Spiriti Antonietta, D’Alò Francesco, Hohaus Stefan, Pagano Livio, Leone Giuseppe, Voso Maria   +16 more
doaj   +1 more source

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors

Chinese Medical Journal, 2020
. Epigenetic regulation includes changes of DNA methylation and modifications of histone proteins and is essential for normal physiologic functions, especially for controlling gene expression.
Qing-Yu Xu, Li Yu, Peng Lyu
doaj   +1 more source

Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 (FLT3)‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience

British Journal of Haematology, EarlyView.
In FMS‐like tyrosine kinase 3 (FLT3)‐mutated relapsed/refractory acute myeloid leukaemia, gilteritinib, azacitidine and venetoclax is an effective salvage option with an ORR of 100% (mCRc [MLFS + CRc] 93%). Sixty‐two per cent of patients treated with intention‐to‐transplant proceeded to allogeneic haematopoietic stem cell transplant, of whom 50% remain
Wei Yee Chan, Hannah Al‐Yousuf, Ho Pui Jeff Lam, Sarah Leong, Jiexin Zheng, Richard Burt, Andrew J. Wilson, Ke Xu, Kate Stringaris, Samah Alimam, Kavita Raj, Rajeev Gupta, Panagiotis Kottaridis, Anish Tailor, Rebecca Burgoyne, Marc R. Mansour, Asim Khwaja, Rob Sellar, Elspeth M. Payne, Jenny O'Nions   +19 more
wiley   +1 more source

Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting

Cancer Management and Research, 2021
Juan Tong, Na Zhao, Xing Hu, Wen Yao, Yaxin Cheng, Li Zhou, Huilan Liu, Liangquan Geng, Zimin Sun, Changcheng Zheng Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and ...
Tong J, Zhao N, Hu X, Yao W, Cheng Y, Zhou L, Liu H, Geng L, Sun Z, Zheng C   +9 more
doaj  

Frailty and Fitness in Older Adults With Acute Myeloid Leukemia: From Chronological Age to Multiparametric Assessment

European Journal of Haematology, EarlyView.
ABSTRACT Acute Myeloid Leukemia predominantly affects older adults, who often present with comorbidities, functional impairment, and frailty, limiting eligibility for intensive chemotherapy or allogeneic transplantation. Historically, treatment options were restricted to hypomethylating agents, low‐dose cytarabine, hydroxyurea, or supportive care, with
Antonella Bruzzese, Enrica Antonia Martino, Santino Caserta, Maria Eugenia Alvaro, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Fortunato Morabito, Ernesto Vigna, Massimo Gentile   +11 more
wiley   +1 more source

KRAS Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations

European Journal of Haematology, EarlyView.
ABSTRACT Somatic mutations in the MAPK signaling pathway are frequently identified at AML diagnosis; however, their impact on treatment resistance and long‐term survival remains unclear. We conducted a retrospective study of patients with newly diagnosed MAPK‐mutated AML seen at the University of Iowa Health Care.
Kensuke Takaoka, Sarah Mott, Ratdanai Yodsuwan, Sakditad Saowapa, Manasawee Tanariyakul, Chalothorn Wannaphut, Kittika Poonsombudlert   +6 more
wiley   +1 more source

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

European Journal of Haematology, EarlyView.
ABSTRACT Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle.
Laurenz Steiner, Lina S. Silva‐Bermudez, Mahmoud Ghazal, Mohammed Abba, Catharina Gerhards, Georgia Metzgeroth, Alice Fabarius, Stefan Klein, Sebastian Kreil, Nanni Schmitt, Patrick Wuchter, Wolf‐Karsten Hofmann, Alexander Streuer   +12 more
wiley   +1 more source

The epigenetic landscape of skeletal muscle in response to exercise and aging

The FEBS Journal, EarlyView.
Epigenetic mechanisms regulate gene expression in response to exercise and aging, thereby supporting skeletal muscle plasticity. Acute exercise induces chromatin remodeling through histone modifications and DNA methylation, promoting the expression of exercise‐responsive genes.
Sabrina Champsi, David A. Hood
wiley   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

The FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture, Devi Nandana, Karthik Ramasamy, Anjan Thakurta   +3 more
wiley   +1 more source